NCT00614523 - Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

July 21, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

November 30, 2015

Conditions

MDSMyelodysplastic SyndromesThrombocytopenia

Interventions

DRUG

Placebo

Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

BIOLOGICAL

Romiplostim

Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.